Cliff Asness's DERM Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 24,877 shares of Journey Medical Corporation (DERM) worth $176,129, representing 0.00% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 4 quarters.
Based on 13F filings, Cliff Asness has maintained this position in DERM for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 24,877 shares. Largest reduction occurred in Q1 2026, reducing 51,270 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Journey Medical Corporation (DERM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Journey Medical Corporation (DERM) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +24,877 | New Buy | 24,877 | $7.08 |
| Q1 2026 | -51,270 | Sold Out | 0 | $0.00 |
| Q4 2025 | +436 | Add 0.86% | 51,270 | $7.71 |
| Q3 2025 | +50,834 | New Buy | 50,834 | $7.12 |
Cliff Asness's Journey Medical Corporation Investment FAQs
Cliff Asness first purchased Journey Medical Corporation (DERM) in Q3 2025, acquiring 50,834 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Journey Medical Corporation (DERM) for 4 quarters since Q3 2025.
Cliff Asness's largest addition to Journey Medical Corporation (DERM) was in Q3 2025, adding 50,834 shares worth $361,938.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 24,877 shares of Journey Medical Corporation (DERM), valued at approximately $176,129.
As of the Q2 2026 filing, Journey Medical Corporation (DERM) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Journey Medical Corporation (DERM) was 51,270 shares, as reported at the end of Q4 2025.